According to BioIntel360, global precision medicine market size is expected to record a CAGR of 11.3% during 2023-2027 to reach US$126,481.5 million by 2027, increasing from US$81,576.2 million in 202...
According to BioIntel360, global precision medicine market size is expected to record a CAGR of 11.3% during 2023-2027 to reach US$126,481.5 million by 2027, increasing from US$81,576.2 million in 2023. Over the last five years, the sector has recorded a CAGR of 10.4% to reach US$73,909.4 million in 2022. Precision medicine can help identify individuals at higher risk diseases and enable early intervention, as well as guide the development of targeted therapies that have the potential to be more effective and have fewer side effects than traditional treatments. As such, precision medicine has become an important area of research and development in the healthcare industry. The precision medicine market is currently experiencing significant growth and is expected to continue to grow in the coming years. The market is being driven by factors such as the increasing prevalence of chronic diseases, growing demand for personalized medicine, and technological advancements in genomics and proteomics. In addition, rising investment in precision medicine research and development is also contributing to market growth. The oncology application segment is expected to hold the largest market share due to the increasing use of precision medicine in cancer treatment. Big Data Has Become A Powerful Tool In Precision Medicine • The Journal of Clinical Oncology Clinical Cancer Informatics recently published a study demonstrating that a big data analytics tool capable of mining vast datasets of various types of cancer or cancer-related diseases has the potential to help researchers identify patterns in potential treatment options and greatly accelerate precision medicine. This sophisticated analytics tool was created by researchers at the University of Michigan Rogel Cancer Center, and it amalgamates multiple datasets to transform medical information into meaningful clinical insights. • Structured data, which is used for statistical analysis, has been deemed the gold standard for cancer research and testing efficacy. To discover cures and various treatment options, cancer researchers depend on “clean data” to produce the required results. On the other hand, unstructured clinical data is more cost-effective to collect than structured data. It is useful for assessing the results of interventions on multiple levels, enabling swift searches, inexpensive storage, and valuable hypothesis generation without requiring to be “clean.” • Despite some limitations to clinical data aggregation, big data has become a powerful tool in precision medicine. As patient-level genomics play an increasingly vital role in precision medicine, big data analytics continues to amplify its influence in cancer research. Numerous healthcare institutions are paving the way for precision medicine by using big data analytics techniques to develop cause-and-effect models from genomic data based on patient populations. New Technological Advancements • Genotype data has been utilised by clinicians as a guide to assist establish the ideal warfarin dose. To assist doctors in maximising pharmacological therapy based on the results of genetic tests, the Clinical Pharmacogenetics Implementation Consortium produced genotype-based drug guidelines. • Genomic profiling of tumors can inform targeted therapy plans for patients with breast or lung cancer. Precision medicine, integrated into healthcare, has the potential to yield diagnoses that are more precise, predict disease risk before symptoms occur, and design customized treatment plans that maximize safety and efficiency. The trend toward enabling the use of precision medicine by establishing data repositories is not restricted to the United States; examples from Biobanks in many countries, such as the UK Biobank, BioBank Japan, and Australian Genomics Health Alliance demonstrate the power of changing attitudes toward precision medicine on a global scale. • Although there is much promise for AI and precision medicine, more work still needs to be done to test, validate, and change treatment practices. Researchers face challenges of adopting unified data formats (e.g., Fast Healthcare Interoperability Resources), obtaining sufficient and high quality labeled data for training algorithms, and addressing regulatory, privacy, and sociocultural requirements. A Glimpse into the Market Dynamics of Precision Medicine • Invitae, a prominent genetics company, has announced that Blue Shield of California has approved commercial coverage for its Personalized Cancer Monitoring (PCM™) assay, which can identify minimal residual disease (MRD) in patients with solid tumors. This policy, which went into effect on March 1, 2023, deems the test necessary for patients with stage I-IV cancer who have undergone surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or progression. • Invitae has announced a collaboration with Epic, a healthcare software company renowned for its industry-leading technology. Invitae will be utilizing Aura, Epic's specialized diagnostics suite, to facilitate interactions with provider organizations within the Epic community, thereby providing genetic insights to inform treatment decisions more easily. This collaboration will enable Invitae to streamline the delivery of test result information in providers' usual workflows, thereby making genetic testing more accessible to both patients and providers across the Epic community. • Precision molecular science biotech Stalicla acquired from Novartis the rights to develop the experimental medication mavoglurant for substance use and neurodevelopmental problems in a multimillion-dollar Swiss agreement. The exclusive, in-licensing arrangement includes secret upfront fees, equity, and up to $270M in marketing and development milestones, as well as further royalties on sales. • Kaiku Health and Novartis expanded their partnership in 2022 after a successful collaboration. The two companies are together to advance precision medicine. Research Initiatives • In recent years, several new initiatives have emerged in addition to ongoing research in genomics. These include IGNITE and CSER-2. The IGNITE program, which stands for 'Implementing GeNomics In Practice', focuses on integrating genomic studies into clinical practice. The program has received funding to support large-scale efforts to incorporate genomic data into electronic tools for more precise patient care. The project involves various models, each with its unique purpose, including establishing a patient's family history, conducting research on genetic markers to prevent diseases, and disseminating information through education. • The National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), on the other hand, have funded CSER-2. The primary goal of this project is to incorporate genomic sequencing into clinical practice and develop genomic medicines in the best interests of patients. Individuals from all occupations will be exposed to this approach in a healthcare setting. • CSER-2 has set forth specific goals to implement this concept, including genome sequencing analysis and identification, researching family history, and connecting patients, families, and healthcare professionals to distribute valid information. Additionally, the project aims to overcome barriers to the implementation of such concepts in real-world medical management. Precision medicine aims to tailor medical treatment to individual patients' needs by understanding the diverse group of patients better. Although various projects and methodologies have been implemented, achieving true precision in healthcare still requires extensive data collection and analysis. The implementation of genomic studies into traditional clinical practice and care has become possible with the new initiatives introduced in the system. The development of more point care designs is crucial, and data analyzed and studied needs to be fed back into the system to understand any flaws or additions that can be made to the outlay. As the field of precision medicine is vast, conducting ample study plans and research is necessary to fully utilize genomics and gene studies to develop proper-targeted disease predictions and probabilities. To increase the importance and utility of precision medicine, any new information found should be checked, rechecked, collected, studied, and disseminated. Overall, the precision medicine market has significant growth potential as the healthcare industry continues to prioritize personalized treatment and disease prevention. The study provides a thorough evaluation of the market revenue with quantitative and qualitative intelligence, and forecasts for the market. The report provides a breakdown of the market into both major and niche segments. Additionally, the study assesses the growth and trends of market revenue on a global, regional, and country level from 2018 to 2027. This comprehensive report offers an extensive data-driven examination of the emerging prospects within the precision medicine industry. It presents a detailed overview of market size and projections across multiple segments, including category, technology platform, by technology, by gene sequencing technology, by drugs, by route of administration, by application, and by end users. Furthermore, the report includes expert commentary on significant trends, drivers, strategies, innovations, and regulations pertaining to the precision medicine market. This title from BioIntel360 provides global and regional insights along with data-centric analysis for the following 5 regions and 20 countries: • Global • North America o United States o Canada o Mexico • Europe o United Kingdom o France o Germany o Italy o Spain • Asia-Pacific o China o Japan o Australia o India o South Korea • Latin America o Brazil o Argentina o Colombia • MEA o Israel o South Africa o Saudi Arabia o Turkey
Insights and data in the report have been segmented under the following six modules: Module 1: Global Precision Medicine Investment Landscape This module provides insights and data related to precision medicine partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of precision medicine investment area. Module 2: Global Precision Medicine Clinical Trial Data Assessment This module evaluates the data available from clinical trials related to precision medicine, representing a bird’s eye view of emerging market dynamics and risks in the diabetes devices & therapeutics sector. Module 3: Global Precision Medicine Patent Data Analysis This module presents an exhaustive study of precision medicine patent analytics at various levels, including strategic research planning as well as analyzing their potential applications. Module 4: Competitive Landscape This module provides detailed information along with a scoring matrix of key companies related to the precision medicine industry, including their historical performance and the latest developments. Module 5: Global Precision Medicine Market Size and Forecast This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the precision medicine market at global, regional and country levels: Precision medicine market share by category • Diagnostics • Therapeutics • Others Precision medicine market share by technology platform • Cloud Based • On-Premises Precision medicine market share by technology • Bioinformatics • Big Data Analytics • Drug Discovery • Companion Diagnostics • Gene Sequencing • Others Precision medicine market share by sequencing technology • Chain Termination Sequencing • Nanopore Sequencing • Sequencing by Ligation • Pyrosequencing • Ion Semiconductor Sequencing • Single Molecule Real Time Sequencing • Sequencing by Synthesis Precision medicine market share by drugs • Mepolizumab • Osimertinib • Aripiprazole Lauroxil • Alectinib • Others Precision medicine market share by route of administration • Injectable • Oral • Others Precision medicine market share by application • Oncology • CNS • Cardiovascular • Infectious Diseases • Others Precision medicine market share by end user • Pharmaceuticals and Biotechnology Companies • Diagnostics Companies • Healthcare IT Specialists/Big Data Companies • Clinical Laboratories Precision medicine market share by region • North America - United States - Canada - Mexico • Europe - France - United Kingdom - Germany - Italy - Spain • Asia-Pacific - China - Japan - Australia - India - South Korea • MEA region - Israel - South Africa - Turkey - Saudi Arabia • Latin America - Brazil - Argentina - Colombia Key Companies Covered • Bayer AG • BioNTech SE • CureVac SE • Personalis, Inc • F. Hoffmann-La Roche Ltd • GSK plc • Immatics Biotechnologies GmbH • Medtronic • Moderna, Inc • NanoString Technologies Module 6 Regulatory Outlook This module contains a detailed understanding of the ethical, legal, and social implications of precision medicine industry.
• Precision Medicine Market Dynamics: Understand market opportunities and key trends along with forecast (2023-2027). Understand market dynamics across various segments such as by category, technology platform, by technology, by gene sequencing technology, by drugs, by route of administration, by application, and by end users. • Competitive Landscape Analysis: Market position and snapshot of key players in the development of precision medicine. Each profile includes a brief overview of the company, information on its therapeutic pipeline, financial data (where available), the most recent events, and future direction of the market. • Clinical Trial Analysis: Insights into opportunities across precision medicine field that have been completed or are still ongoing, using parameters such as trial status, trial registration year, an indication of the target disease, trial phase, patient enrolment, and sponsor/collaborator type. • Develop Market-Specific Strategies: Identify growth segments based on a thorough analysis of the Precision Medicine patents that have been applied for or granted based on the patent type, the issuing agency, and patent offices involved, the Cooperative Patent Classification (CPC) symbols, the firm type, significant industry and non-industry participants (based on many patents), and discrete patent assignees. • Financial Deals Insights: Get insights into various precision medicine partnerships that have been developed, including those for research and development (R&D), clinical trials, mergers and acquisitions, product development, commercialization, licencing, and manufacturing. A complete analysis of the various investments made in companies that specialise in developing drugs using precision medicine technologies.
This market intelligence report features an in-depth analysis on the current market dynamics of the precision medicine market. It provides a detailed analysis of precision medicine market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 35 sections, 700+ tables, and 1000+ charts. Chapter 1 About this Report 1.1 Research Methodology 1.2 Definitions 1.3 Disclaimer Chapter 2 Global Precision Medicine Market Outlook and Future Growth Dynamics 2.1 Introduction 2.2 Market Opportunities and Growth Dynamics 2.3 Strategy and Innovations 2.4 Regulation and Challenges Related to Precision Medicine Around the Globe Chapter 3 Regulatory Dynamics Assessment Across Different regions 3.1 North America Precision Medicine Regulations 3.2 Europe Precision Medicine Regulations 3.3 Asia Pacific Precision Medicine Regulations 3.4 Latin America Precision Medicine Regulations 3.5 Middle East & Africa region Precision Medicine Regulation Chapter 4 Global Precision Medicine Market Insights 4.1 Newly Approved Personalized Molecular Entities in 2021 4.2 Percentage of Newly Approved Personalized Medicines, by Treatment Type 4.3 Precision Medicines as a Percentage of FDA Approved New Molecular Entities from 2014 to 2021 4.4 Percentage of Precision Medicines in Development as of 2022, by Type 4.5 Number of Precision Medicines Available in the US from 2008 to 2020 4.6 Percentage of New Molecular Entities Classified as Precision Medicine at FDA 4.7 List of Countries or Territories with the Highest Total Health Expenditure (USD Billion) Due to Diabetes (20–79 years) in 2022 4.8 Technological Advancement Since Completion of Human Genome Project 4.9 Most Relevant Data Types for Precision Medicine 4.10 Geographical Breakdown Of Sales of New Launched Medicines, 2015-2021 4.11 Top Opportunities for Precision Medicine by 2030 4.12 Precision Medicine, 2021 vs 2030 4.13 Future and Vision of Precision Medicine Chapter 5 Global Precision Medicine Financial Deals & Alliances Market Dynamics & Outlook 5.1 Precision Medicine Financial Deals & Alliances Market Prediction and Estimation 5.2 Precision Medicine Partnerships Vs Mergers & Acquisition, 2022 vs 2025 5.3 Precision Medicine Financial Deals Analysis by Category, 2022 vs 2025 5.4 Precision Medicine Financial Deals Analysis by Technology Platforms, 2022 vs 2025 5.5 Precision Medicine Financial Deals Analysis by Region, 2022 vs 2025 5.6 Precision Medicine Financial Deals Analysis by Funding Type, 2018-2022 5.7 Precision Medicine Financial Deals Analysis by Funding Stage, 2018-2022 5.8 Recent Deals and Partnership of Precision Medicine 5.9 Global Precision Medicine Deals Landscape, 2020-2022 Chapter 6 Global Precision Medicine Patent Analysis & Outlook 6.1 Precision Medicine Historical and Futuristic Trend of Patent, 2018-2027 6.2 Precision Medicine Patent Analysis by Type of Players, 2022 vs 2025 6.3 Precision Medicine Patent Analysis by Patent Type, 2018-2022 6.4 Precision Medicine Patent Analysis by Legal Status, 2018-2022 6.5 Precision Medicine Patent Analysis by Top Patent Owners 6.6 Precision Medicine Patent Analysis by Top Patent Applicants 6.7 Precision Medicine: Precision Medicine Top Patent Applicants Benchmarking Analysis 6.8 Precision Medicine Patent Analysis by Published Status 6.9 Precision Medicine Patent Analysis by Investors 6.10 Precision Medicine Patent Analysis by CPC Classification Code 6.11 Precision Medicine Patent Documents by Jurisdiction 6.12 List of Recent Precision Medicine Patents Chapter 7 Precision Medicine Clinical Trial Analysis & Outlook 7.1 Precision Medicine Clinical Trial Historical and Futuristics Trend 7.2 Precision Medicine Clinical Trial Region-wise Prediction & Estimation, 2018-2027 7.3 Precision Medicine Clinical Trial Analysis by Country-wise Analysis 7.4 Precision Medicine Clinical Trial Analysis by Age Group 7.5 Precision Medicine Clinical Trial Analysis by Funding Agency 7.6 Precision Medicine Clinical Trial Analysis by Documents 7.7 Precision Medicine Clinical Trial Analysis by Phase-wise 7.8 Precision Medicine Clinical Trial Analysis by Status 7.9 Precision Medicine Clinical Trial Analysis by Study Type Chapter 8 Precision Medicine Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives 8.1 Precision Medicine Competitive Index Ranking & Attractiveness Quadrant 8.2 Precision Medicine Company Market Share 8.3 Precision Medicine Competitive Mapping Quadrant 8.4 Key Companies by Regions 8.5 Competitive Landscape by Category of Precision Medicine 8.6 Precision Medicine Company Profiles 8.6.1 Bayer AG 8.6.2 BioNTech SE 8.6.3 CureVac SE 8.6.4 Personalis, Inc 8.6.5 F. Hoffmann-La Roche Ltd 8.6.6 GSK plc 8.6.7 Immatics Biotechnologies GmbH 8.6.8 Medtronic 8.6.9 Moderna, Inc 8.6.10 NanoString Technologies Chapter 9 Global Precision Medicine Market Size and Forecast, 2018-2027 9.1 Global Precision Medicine Market Share by Category, 2018-2027 9.2 Global Precision Medicine Market Share by Technology Platforms, 2018-2027 9.3 Global Precision Medicine Market Share by Technology, 2018-2027 9.4 Global Precision Medicine Market Share by Gene Sequencing, 2018-2027 9.5 Global Precision Medicine Market Share by Drugs, 2018-2027 9.6 Global Precision Medicine Market Share by Route of Administration, 2018-2027 9.7 Global Precision Medicine Market Share by Application, 2018-2027 9.8 Global Precision Medicine Market Share by End User, 2018-2027 Chapter 10 – Chapter 35: This section contains chapters providing precision medicine market sizing and forecast for additional 20 countries and 5 regions.
Table 1: Precision Medicine Financial Deals Market Size and Forecast, by Value (USD Million), 2018-2027 Table 2: Precision Medicine Financial Deals Market Size and Forecast, by Volume, 2018-2027 Table 3: Global Precision Medicine Market Size by Value (USD MM) 2018-2027 Table 4: Global Precision Medicine Market Size by Diagnosis, by Value (USD MM), 2018-2027 Table 5: Global Precision Medicine Market Size by Therapeutics, by Value (USD MM) 2018-2027 Table 6: Global Precision Medicine Market Size by Others, by Value (USD MM) 2018-2027 Table 7: Global Precision Medicine Market Size by Cloud Based Platform, by Value (USD MM) 2018-2027 Table 8: Global Precision Medicine Market Size by On-Premise Platform, by Value (USD MM) 2018-2027 Table 9: Global Precision Medicine Market Size by Bioinformatics, by Value (USD MM) 2018-2027 Table 10: Global Precision Medicine Market Size by Big Data Analytics, by Value (USD MM) 2018-2027 Table 11: Global Precision Medicine Market Size by Drug Discovery, by Value (USD MM) 2018-2027 Table 12: Global Precision Medicine Market Size by Companion Diagnostics, by Value (USD MM) 2018-2027 Table 13: Global Precision Medicine Market Size by Gene Sequencing, by Value (USD MM) 2018-2027 Table 14: Global Precision Medicine Market Size by Others, by Value (USD MM) 2018-2027 Table 15: Global Precision Medicine Market Size by Chain Termination Sequencing, by Value (UDS MM) 2018-2027 Table 16: Global Precision Medicine Market Size by Nanopore Sequencing, by Value (UDS MM) 2018-2027 Table 17: Global Precision Medicine Market Size by Sequencing by Ligation, by Value (UDS MM) 2018-2027 Table 18: Global Precision Medicine Market Size by Pyrosequencing, by Value (UDS MM) 2018-2027 Table 19: Global Precision Medicine Market Size by Ion Semiconductor Sequencing, by Value (UDS MM) 2018-2027 Table 20: Global Precision Medicine Market Size by Single Molecule Real Time Sequencing, by Value (UDS MM) 2018-2027 Table 21: Global Precision Medicine Market Size by Sequencing by Synthesis, by Value (UDS MM) 2018-2027 Table 22: Global Precision Medicine Market Size by Mepolizumab, by Value (USD MM), 2018-2027 Table 23: Global Precision Medicine Market Size by Osimertinib, by Value (USD MM), 2018-2027 Table 24: Global Precision Medicine Market Size by Aripiprazole Lauroxil, by Value (USD MM), 2018-2027 Table 25: Global Precision Medicine Market Size by Alectinib, by Value (USD MM), 2018-2027 Table 26: Global Precision Medicine Market Size by Others, by Value (USD MM), 2018-2027 Table 27: Global Precision Medicine Market Size by Injectable (USD MM), 2018-2027 Table 28: Global Precision Medicine Market Size by Oral (USD MM), 2018-2027 Table 29: Global Precision Medicine Market Size by Others (USD MM), 2018-2027 Table 30: Global Precision Medicine Market Size by Oncology, by Value (USD MM), 2018-2027 Table 31: Global Precision Medicine Market Size by CNS, by Value (USD MM), 2018-2027 Table 32: Global Precision Medicine Market Size by Cardiovascular, by Value (USD MM), 2018-2027 Table 33: Global Precision Medicine Market Size by Infectious Diseases, by Value (USD MM), 2018-2027 Table 34: Global Precision Medicine Market Size by Others, by Value (USD MM), 2018-2027 Table 35: Global Precision Medicine Market Size by Pharmaceuticals and Biotechnology Companies, by Value (USD MM), 2018-2027 Table 36: Global Precision Medicine Market Size by Diagnostics Companies, by Value (USD MM), 2018-2027 Table 37: Global Precision Medicine Market Size by Healthcare IT Specialists/Big Data Companies, by Value (USD MM), 2018-2027 Table 38: Global Precision Medicine Market Size by Clinical Laboratories, by Value (USD MM), 2018-2027
Figure 1: BioIntel360 Research Methodology Figure 2: Major Milestones of Precision Medicine Figure 3: Newly Approved Personalized Molecular Entities in 2021 Figure 4: Percentage of Newly Approved Personalized Medicines, by Treatment Type Figure 5: Precision Medicines as a Percentage of FDA Approved New Molecular Entities from 2014 to 2021 Figure 6: Percentage of Precision Medicines in Development as of 2022, by Type Figure 7: Number of Precision Medicines Available in the US from 2008 to 2020 Figure 8: Percentage of New Molecular Entities Classified as Precision Medicine at FDA Figure 9: List of Countries or Territories with the Highest Total Health Expenditure (USD Billion) Due to Diabetes (20–79 years) in 2022 Figure 10: Technological Advancement Since Completion of Human Genome Project Figure 11: Most Relevant Data Types for Precision Medicine Figure 12: Most Relevant Data Types for Precision Medicine Figure 13: Top Opportunities for Precision Medicine by 2030 Figure 14: Precision Medicine, 2021 vs 2030 Figure 15: Future and Vision of Precision Medicine Figure 16: Precision Medicine Financial Deals & Alliances Market Size and Forecast, by Value (USD Million), 2018-2027 Figure 17: Precision Medicine Financial Deals & Alliances Market Share and Forecast, by Volume (%), 2018-2027 Figure 18: Global Precision Medicine: Partnerships Vs Mergers & Acquisition Analysis, 2022 vs 2025 Figure 19: Global Precision Medicine Financial Deals: Analysis by Category, 2022 vs 2025 Figure 20: Global Precision Medicine Financial Deals: Analysis by Technology Platforms, 2022 vs 2025 Figure 21: Global Precision Medicine Financial Deals: Analysis by Region, 2022 vs 2025 Figure 22: Global Precision Medicine Financial Deals: Analysis by Funding Type, 2018-2022 Figure 23: Global Precision Medicine Financial Deals: Analysis by Funding Stage, 2018-2022 Figure 24: Recent Deals and Partnership of Precision Medicine Figure 25: Global Precision Medicine Deals (> USD 1 Billion) Landscape, 2020-2022 Figure 26: Precision Medicine Historic & Futuristics Trends of Patent, by Volume, 2018-2027 Figure 27: Precision Medicine Patent: Analysis by Type of Players, 2022 vs 2025 Figure 28: Precision Medicine Patent: Analysis by Patent Type, 2018-2022 Figure 29: Precision Medicine Patent: Analysis by Patent Legal Status, 2018-2022 Figure 30: Precision Medicine Patent: Analysis by Top Patent Owners, 2022 Figure 31: Precision Medicine Patent: Analysis by Top Patent Applicants, 2022 Figure 32: Precision Medicine Key Patent Applicant: Genome Int Corporation and CPC Classification Code Analysis., 2022 Figure 33: Precision Medicine Key Patent Applicant: Univ Indiana Res & Tech Corp and CPC Classification Code Analysis, 2022 Figure 34: Precision Medicine Key Patent Applicant: Caris Mpi Inc and CPC Classification Code Analysis, 2022 Figure 35: Precision Medicine Key Patent Applicant: Jiangsu Provincial Hospital Tcm and CPC Classification Code Analysis, 2022 Figure 36: Precision Medicine Key Patent Applicant: Nanjing Hichang Traditional Chinese Medicine Group Ltd Company and CPC Classification Code Analysis, 2022 Figure 37: Precision Medicine Patent: Analysis by Published Status, 2018-2022 Figure 38: Precision Medicine Patent: Analysis by Investors, 2022 Figure 39: Precision Medicine Patent: Analysis by CPC Classification Code, 2022 Figure 40: Precision Medicine Patent: Analysis by Documents by Jurisdiction, 2022 Figure 41: List of Recent Precision Medicine Patents Figure 42: Precision Medicine Clinical Trial Historical and Futuristics Trend, by Volume, 2018-2027 Figure 43: Precision Medicine Clinical Trial Region-wise Share and Forecast, by Volume (%), 2018-2027 Figure 44: Precision Medicine Clinical Trial: Analysis by Country-wise Figure 45: Precision Medicine Clinical Trial: Analysis by Age Group Figure 46: Precision Medicine Clinical Trial: Analysis by Funding Agency Figure 47: Precision Medicine Clinical Trial: Analysis by Documents Figure 48: Precision Medicine Clinical Trial: Analysis by Phase-wise Figure 49: Precision Medicine Clinical Trial: Analysis by Status Figure 50: Precision Medicine Clinical Trial: Analysis by Study Type Figure 51: Precision Medicine Companies Competitive Landscape Figure 52: Precision Medicine: Companies by Market Share, 2022 Figure 53: Precision Medicine Companies Mapping Quadrant Figure 54: Precision Medicine: Companies by Geography Figure 55: Precision Medicine: Companies by Type of Category Figure 56: Global Precision Medicine Market Size by Value (USD MM) 2018-2027 Figure 57: Global Precision Medicine Market Share by Category (%), 2018-2027 Figure 58: Global Precision Medicine Market Size by Diagnosis, by Value (USD MM), 2018-2027 Figure 59: Global Precision Medicine Market Size by Therapeutics, by Value (USD MM) 2018-2027 Figure 60: Global Precision Medicine Market Size by Others, by Value (USD MM) 2018-2027 Figure 61: Global Precision Medicine Market Share by Technology Platforms (%), 2018-2027 Figure 62: Global Precision Medicine Market Size by Cloud Based Platform, by Value (USD MM) 2018-2027 Figure 63: Global Precision Medicine Market Size, by On-Premise Platform, by Value (USD MM) 2018-2027 Figure 64: Global Precision Medicine Market Share by Technology (%), 2018-2027 Figure 65: Global Precision Medicine Market Size by Bioinformatics, by Value (USD MM) 2018-2027 Figure 66: Global Precision Medicine Market Size by Big Data Analytics, by Value (USD MM) 2018-2027 Figure 67: Global Precision Medicine Market Size by Drug Discovery, by Value (USD MM) 2018-2027 Figure 68: Global Precision Medicine Market Size by Companion Diagnostics, by Value (USD MM) 2018-2027 Figure 69: Global Precision Medicine Market Size by Gene Sequencing, by Value (USD MM) 2018-2027 Figure 70: Global Precision Medicine Market Size by Others, by Value (USD MM) 2018-2027 Figure 71: Global Precision Medicine Market Share by Gene Sequencing (%), 2018-2027 Figure 72: Global Precision Medicine Market Share by Chain Termination Sequencing, by Value (UDS MM) 2018-2027 Figure 73: Global Precision Medicine Market Share by Nanopore Sequencing, by Value (UDS MM) 2018-2027 Figure 74: Global Precision Medicine Market Share by Sequencing by Ligation, by Value (UDS MM) 2018-2027 Figure 75: Global Precision Medicine Market Share by Pyrosequencing, by Value (UDS MM) 2018-2027 Figure 76: Global Precision Medicine Market Share by Ion Semiconductor Sequencing, by Value (UDS MM) 2018-2027 Figure 77: Global Precision Medicine Market Share by Single Molecule Real Time Sequencing, by Value (UDS MM) 2018-2027 Figure 78: Global Precision Medicine Market Share by Sequencing by Synthesis, by Value (UDS MM) 2018-2027 Figure 79: Global Precision Medicine Market Share by Drugs (%), 2018-2027 Figure 80: Global Precision Medicine Market Size by Mepolizumab, by Value (USD MM), 2018-2027 Figure 81: Global Precision Medicine Market Size by Osimertinib, by Value (USD MM), 2018-2027 Figure 82: Global Precision Medicine Market Size by Aripiprazole Lauroxil, by Value (USD MM), 2018-2027 Figure 83: Global Precision Medicine Market Size by Alectinib, by Value (USD MM), 2018-2027 Figure 84: Global Precision Medicine Market Size by Others, by Value (USD MM), 2018-2027 Figure 85: Global Precision Medicine Market Share by Route of Administration (%), 2018-2027 Figure 86: Global Precision Medicine Market Size by Injectable (USD MM), 2018-2027 Figure 87: Global Precision Medicine Market Size by Oral (USD MM), 2018-2027 Figure 88: Global Precision Medicine Market Size by Others (USD MM), 2018-2027 Figure 89: Global Precision Medicine Market Share by Application (%), 2018-2027 Figure 90: Global Precision Medicine Market Size by Oncology, by Value (USD MM), 2018-2027 Figure 91: Global Precision Medicine Market Size by CNS, by Value (USD MM), 2018-2027 Figure 92: Global Precision Medicine Market Size by Cardiovascular, by Value (USD MM), 2018-2027 Figure 93: Global Precision Medicine Market Size by Infectious Diseases, by Value (USD MM), 2018-2027 Figure 94: Global Precision Medicine Market Size by Others, by Value (USD MM), 2018-2027 Figure 95: Global Precision Medicine Market Share by End User (%), 2018-2027 Figure 96: Global Precision Medicine Market Size by Pharmaceuticals and Biotechnology Companies, by Value (USD MM), 2018-2027 Figure 97: Global Precision Medicine Market Size by Diagnostics Companies, by Value (USD MM), 2018-2027 Figure 98: Global Precision Medicine Market Size by Healthcare IT Specialists/Big Data Companies, by Value (USD MM), 2018-2027 Figure 99: Global Precision Medicine Market Size by Clinical Laboratories, by Value (USD MM), 2018-2027
